Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets

Abstract

This study demonstrates that the HA family can be exploited for developing a biomarker-driven, targeted treatment for bladder cancer, and 4MU, a non-toxic oral HA synthesis inhibitor, is one such candidate.